Clinical trial Recruiting at 23 sites Interventional Ages 18 and up

Comparing reduced stent strategy with conventional stent treatment for heart attack patients

Official title: Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)

Run by Hospital Universitario La Fe · NCT06353594 · Data updated 2026-11-12

This study tests whether using drug-coated balloons instead of regular stents can help heart attack patients recover better after treatment.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1272 (estimated)
SponsorHospital Universitario La Fe
Academic / other
Locations23 sites (Huelva, Huelva and 22 other locations)
StatusRecruiting
StartedMarch 11, 2024
Main results expectedSeptember 2026
Study endsSeptember 2035
Registry record updatedMay 28, 2026
Trial IDNCT06353594 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients presenting with STEMI who require percutaneous coronary intervention.

Probably not a fit

Patients with severe comorbidities, such as life expectancy less than one year or significant heart failure, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of a reduced stent strategy using drug-coated balloons (DCB) compared to the conventional approach of using drug-eluting stents (DES) in patients experiencing ST-segment myocardial infarction (STEMI). Patients will be randomly assigned to either the DCB-based strategy or the DES-based strategy after successful guidewire crossing and restoration of blood flow. The study seeks to determine which method provides better outcomes for patients undergoing percutaneous coronary intervention (PCI).

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for heart attack patients, potentially reducing complications associated with stent placement.

How similar studies have gone: Other studies have explored similar approaches in coronary interventions, but the specific reduced stent strategy using DCB in STEMI patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

\- Patients presenting with STEMI and indication to undergo pPCI.

Exclusion Criteria:

* Life expectancy \<1 year due 1 to non-cardiac disease.
* Inability to provide informed consent.
* Cardiogenic shock.
* Left ventricular ejection fraction \<15%.
* Left main disease.
* Stent thrombosis
* Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions).
* Patients with chronic total occlusions.
* Untreatable coronary disease.
* Non-identified culprit lesion.
* Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.

Where it's running

  • Hospital Universitario Juan Ramón Jiménez
    Huelva, Huelva, Spain
    Recruiting
  • Hospital Universitario Y Politecnico La Fe
    Valencia, Valencia, Spain
    Recruiting
  • Complejo Hospitalario Universitario de A Coruña
    A Coruña, Spain
    Recruiting
  • Hospital Universitario de Burgos
    Burgos, Spain
    Recruiting
  • Consorcio Hospitalario Provincial de Castellon
    Castelló, Spain
    Recruiting
  • Hospital Universitario Reina Sofía de Córdoba
    Córdoba, Spain
    Recruiting
Show 17 more locations
  • Hospital General Universitario de Elche
    Elche, Spain
    Recruiting
  • Hospital Universitario Clínico San Cecilio
    Granada, Spain
    Recruiting
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Spain
    Recruiting
  • Hospital Universitario de La Princesa
    Madrid, Spain
    Recruiting
  • Hospital Universitario La Paz
    Madrid, Spain
    Recruiting
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, Spain
    Recruiting
  • Hospital Universitario Regional de Malaga
    Málaga, Spain
    Recruiting
  • Hospital de Mérida
    Mérida, Spain
    Recruiting
  • Hospital Universitario de Navarra
    Pamplona, Spain
    Recruiting
  • Complejo Hospitalario Universitario de Santiago de Compostela
    Santiago de Compostela, Spain
    Recruiting
  • Hospital Universitario Virgen Del Rocio
    Seville, Spain
    Recruiting
  • Hospital Universitari Joan Xxiii de Tarragona
    Tarragona, Spain
    Recruiting
  • Hospital Universitario Mutua de Terrassa
    Terrassa, Spain
    Recruiting
  • Consorcio Hospital General Universitario de Valencia
    Valencia, Spain
    Recruiting
  • Hospital Clinico Universitario de Valladolid
    Valladolid, Spain
    Recruiting
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, Spain
    Recruiting
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
    Recruiting

Study contacts

  • Principal investigator: Jorge Sanz Sánchez, PI — Hospital Universitario La Fe
  • Study coordinator: Naiara García Lamas
  • Email: naiara@pinvestiga.com
  • Phone: 634213101

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.